Synaptotagmin 1 Protein (Syt1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox gene}}
SYNAPTOTAGMIN 1 PROTEIN is a gene/protein encoding a key neuronal protein involved in synaptic function, signal transduction, and cellular homeostasis. Dysfunction of SYNAPTOTAGMIN 1 PROTEIN is associated with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and related disorders.
| Protein Name | Synaptotagmin-1 (SYT1) |
|---|---|
| Gene | SYT1 |
| UniProt ID | P21579 |
| PDB ID | 1K5W, 1LJZ, 2R83 |
| Molecular Weight | 62 kDa |
| Subcellular Localization | Synaptic vesicles, presynaptic terminal |
| Protein Family | Synaptotagmin family (C2 domain proteins) |
Synaptotagmin-1 is a type I membrane protein with a distinctive structure:
N-terminal transmembrane anchor: Transmembrane region that localizes SYT1 to synaptic vesicle membranes
C2A domain (C2 domain A): First C2 domain that binds 3 Ca²⁺ ions. Critical for Ca²⁺-dependent phospholipid binding and interactions with the SNARE complex.
C2B domain (C2 domain B): Second C2 domain that binds 3 Ca²⁺ ions. Essential for synaptotagmin dimerization and interaction with syntaxin-1.
Linker region: Flexible hinge region connecting the C2 domains to the transmembrane anchor.
The C2 domains adopt a β-sandwich fold with loops that coordinate calcium ions. The structure allows SYT1 to function as a dual Ca²⁺ sensor for synaptic vesicle exocytosis.
Synaptotagmin-1 is the primary calcium sensor for fast synchronous neurotransmitter release at synapses. When an action potential arrives at the presynaptic terminal, voltage-gated calcium channels (VGCCs) open, allowing Ca²⁺ ions to influx. SYT1 binds Ca²⁺ with high affinity (Kd ~10 μM) and triggers synaptic vesicle fusion through interaction with the SNARE complex.
The mechanism involves:
SYT1 regulates different synaptic vesicle pools:
Readily releasable pool (RRP): SYT1 primarily controls fusion of vesicles in the RRP, which are docked at active zones.
Synchronous vs asynchronous release: SYT1 is specifically required for fast, synchronous release. Asynchronous release continues in SYT1-deficient synapses.
SNARE Complex: SYT1 interacts with SNAP-25, syntaxin-1A, and VAMP2 to facilitate vesicle fusion. The C2B domain binds to syntaxin-1A in a Ca²⁺-dependent manner.
Voltage-Gated Calcium Channels: Couples Ca²⁺ influx to vesicle release. Specifically interacts with Cav2.1 (P/Q-type) and Cav2.2 (N-type) channels.
Doc2B: May function as backup calcium sensor for asynchronous release.
Phospholipid membranes: C2 domains bind to phospholipid bilayers in a Ca²⁺-dependent manner, facilitating membrane penetration.
Multiple SYT1 isoforms exist through alternative splicing:
SYT1 contributes to synaptic plasticity mechanisms:
Alterations in SYT1 expression and function contribute to AD pathophysiology:
Synaptic dysfunction: SYT1 levels are reduced in AD brain, contributing to synaptic vesicle cycling deficits.
Amyloid-β effects: Aβ oligomers can interfere with SYT1-SNARE interactions, impairing neurotransmitter release.
Calcium dysregulation: AD-related calcium dysregulation affects SYT1 function and synaptic plasticity.
Presynaptic markers: SYT1 is being investigated as a presynaptic biomarker for synaptic dysfunction in AD.
Research findings: Studies show altered SYT1 expression in AD hippocampus and cortex, correlating with cognitive decline.
SYT1 involvement in PD:
Dopaminergic terminals: SYT1 is critical for vesicle cycling in dopaminergic neurons of the substantia nigra.
α-Synuclein interactions: α-Synuclein can affect synaptic vesicle dynamics and potentially interact with SYT1.
Synaptic vesicle recycling: Impaired vesicle recycling contributes to neurotransmitter deficits in PD.
Therapeutic implications: Enhancing synaptic vesicle function represents a potential therapeutic strategy.
SYT1 in ALS:
Presynaptic dysfunction: SYT1 alterations contribute to motor neuron synaptic deficits.
Synaptic vesicle pools: Abnormalities in vesicle pool dynamics affect neuromuscular junction function.
Protein aggregates: TDP-43 and FUS pathology can affect SYT1 mRNA processing.
Therapeutic targets: Modulating synaptic function is being explored for ALS treatment.
SYT1 as a biomarker:
Targeting SYT1 pathways:
Key SYT1-interacting proteins:
Studying SYT1:
The study of Synaptotagmin 1 Protein (Syt1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.